Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Completed · Phase 1
Conditions studied: B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL, Follicular Lymphoma Grade 3B
In brief
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
Key facts
- Study ID
- NCT04088890
- Run by
- Matthew Frank
- People needed
- 52
- Starts
- 2019-09-12
- Expected to finish
- 2025-03-07
- Last updated by the study team
- 2026-03-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford Medical Center — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.